Layoffs
ArsenalBio sheds most of staff in pivot to in vivo CAR-T
September 1, 2026
Biotech
Layoffs
Key Facts
Signal Type
Layoffs
Industry
Biotech
Companies
ArsenalBio, Bristol Myers Squibb, Regeneron, Genentech, Eli Lilly
Date
September 1, 2026
ArsenalBio announced a major restructuring, laying off 99 employees—the majority of its workforce—and halting all development of its ex vivo clinical assets. The company is pivoting to in vivo CAR-T therapy, a crowded field with competitors including Eli Lilly, Johnson & Johnson, AstraZeneca, and Gilead's Kite Pharma. CEO Ken Drazan stated the decision was not made lightly.
The layoffs affect most of the company across all teams, functions, and locations. After a previous layoff in September 2025, ArsenalBio had 127 workers; now only a small fraction remains. The lead asset AB-2100 is no longer in the pipeline, which now features early clinical-stage AB-3028 (prostate cancer) and preclinical AB-7000.
ArsenalBio was a fundraising powerhouse, raising $325 million with backing from Bristol Myers Squibb and Regeneron, plus a partnership with Genentech. The pivot to in vivo CAR-T signals challenges in solid tumor CAR-T development and may trigger M&A activity as the company seeks strategic opportunities for its existing technology and assets.
ArsenalBio is actively seeking strategic opportunities for its existing technology and assets, which could lead to partnerships, asset sales, or acquisition. The success of its in vivo pivot will depend on technology differentiation and securing new funding in a competitive landscape.
Source:
Fierce BiotechGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
